// App-Quantinova.ai

3118 : Expression of end-binding protein 1 (EB1), a potential response-predictive biomarker for lisavanbulin, in glioblastoma and various other solid tumor types.

Researchers

Presenter

  • Magdalena Skowronska

Principal Investigators

  • Crescens Diane Tiu

  • Alexandar Tzankov

  • Fatima Knig

  • Joanne Lewis

  • Igor Vivanco

  • Malte Kleinschmidt

  • Kirk Beebe

  • Stephanie Anderson

  • Felix Bachmann

  • Marc Engelhardt

  • Heidi A Lane

  • Thomas Kaindl

  • Alexandru C Stan

  • Elizabeth Ruth Plummer

  • T.R. Jeffry Evans

  • Inti Zlobec

  • Juanita Suzanne Lopez

Medical Centers

  • Institute of Pathology, University of Bern, Bern, Switzerland

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Institute for Pathology, University Hospital Basel, Basel, Switzerland

  • Targos Molecular Pathology GmbH, Kassel, Germany

  • Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

  • Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom

  • GeneCentric Therapeutics Inc., Durham, NC, Basilea Pharmaceutica International Ltd., Basel, Switzerland

  • Basilea Pharmaceutica International Ltd, Basel, Switzerland

  • Department of Pathology, Neuropathology, The Queen Elizabeth University Hospital, The Royal Hospital for Children, NHS GGC, Glasgow, United Kingdom

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Locations

  • Switzerland

  • United Kingdom

  • Germany

Companies

  • Targos Molecular Pat

  • Basilea Pharmaceutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • BAL-101553

  • BAL-27862

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02490800

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved